Good
Mostly Aligned
Patient Risk:
Moderate
Summary
Most statements are supported by the provided JARDIANCE label excerpts (SGLT2 increases urinary glucose, genitourinary infections risk, and mechanism). However, several claims are either generalized beyond the provided label or include an unsupported negative framing about using Jardiance specifically to prevent UTIs and about switching/successfully preventing UTIs.
Category Scores
Accurate Statements
Jardiance (empagliflozin) is an SGLT2 inhibitor used for type 2 diabetes.
Supported by JARDIANCE indication for type 2 diabetes mellitus (Section 1) and mechanism of action as an SGLT2 inhibitor with increased urinary glucose excretion (Section 12.1).
Jardiance is used to reduce risk of certain heart and kidney outcomes.
Supported by indications to reduce cardiovascular death and hospitalization for heart failure in adults with heart failure; reduce risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease; and reduce risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease (Section 1), and supportive study summaries (Sections 14.4 and 14.5).
SGLT2 inhibitors increase glucose in urine.
Supported by mechanism of action: empagliflozin increases urinary glucose excretion (Section 12.1).
Increasing glucose in urine can raise the risk of genital yeast infections.
Supported that JARDIANCE increases urinary glucose excretion (Section 12.1) and increases risk of genitourinary infections including genital mycotic infections (Section 5.3).
Jardiance can contribute to more urinary tract–related symptoms in some people.
Supported that JARDIANCE increases risk of genitourinary infections including urinary tract infections (Section 5.3). (Label excerpt does not explicitly use the word 'symptoms' but supports UTI occurrence.)
Some people experience more urinary infections or symptoms after starting an SGLT2 inhibitor.
Supported by labeling that serious genitourinary infections including urinary tract infections have occurred with SGLT2 inhibitors (Section 5.3).
If a person has a history of recurrent UTIs, their risk profile may be higher than average when taking an SGLT2 inhibitor.
Partially supported: label excerpt indicates increased risk of genitourinary infections and that serious infections have occurred; however, it does not specifically mention 'recurrent UTIs' or a differential risk statement for that history in the provided text (Section 5.3 provided).
The underlying mechanism (more glucose in urine) applies across SGLT2 inhibitors.
Supported for empagliflozin as SGLT2 inhibitor increases urinary glucose excretion (Section 12.1). (Provided label excerpts do not explicitly state that all SGLT2 inhibitors share the same mechanism wording, but empagliflozin is directly supported.)
Unsupported Statements
Jardiance may be a questionable choice if the goal is specifically to prevent UTIs.
The provided label excerpts do not state or imply that Jardiance is 'questionable' for UTI prevention or that it is intended/contraindicated for preventing UTIs; they only describe increased risk of genitourinary infections (Sections 5.3 and 12.1).
Switching within the SGLT2 class or changing dose usually does not solve UTI prevention simply by switching to another SGLT2.
The provided label excerpts do not address switching between SGLT2 inhibitors or dose changes as a strategy for preventing UTIs, nor do they state 'usually does not solve' UTI prevention (Sections provided cover risk and monitoring/discontinuation when suspected, but not switching guidance for UTI prevention).
If a person has a history of recurrent UTIs, their risk profile may be higher than average when taking an SGLT2 inhibitor.
The provided excerpts do not mention recurrent UTIs as a specific risk modifier or provide an explicit 'higher than average' statement tied to that history (Section 5.3 provided does not include this detail).
Contradictions
Important Omissions
For genitourinary infections, the label excerpt includes an action to immediately evaluate genital/perineal pain/swelling/erythema/swelling and to discontinue JARDIANCE if suspected, with prompt medical/surgical intervention. None of the AI claims included these management instructions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Claims broadly reflect labeling that JARDIANCE increases urinary glucose excretion and raises risk of genitourinary infections, but two statements introduce unsupported guidance about using/switching Jardiance to prevent UTIs and omit label-described evaluation/discontinuation actions for suspected serious genitourinary infections.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Two claims are not supported by the provided label excerpts: (1) negative framing about suitability specifically to prevent UTIs and (2) assertions about switching/dose changes solving UTI prevention.
Suggested Improvement
Rephrase unsupported statements to match label language (e.g., emphasize that JARDIANCE increases urinary glucose excretion and increases risk of genitourinary infections; include the label-supported need to immediately evaluate suspected serious genital/perineal infections and discontinue JARDIANCE if suspected).